{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:19:51Z","timestamp":1761718791599,"version":"3.40.5"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1111\/bjh.15912","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:31:39Z","timestamp":1554262299000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Venetoclax is an option in B\u2010cell prolymphocytic leukaemia following progression on B\u2010cell receptor pathway inhibitors"],"prefix":"10.1111","volume":"186","author":[{"given":"Nikila","family":"Patil","sequence":"first","affiliation":[{"name":"Department of Haematology Rotherham Foundation Trust Rotherham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-2289","authenticated-orcid":false,"given":"Richard G.","family":"Went","sequence":"additional","affiliation":[{"name":"Department of Haematology Rotherham Foundation Trust Rotherham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01680.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380139"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01069.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14066"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14224"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097717"},{"volume-title":"Venetoclax for treating chronic lymphocytic leukaemia (NICE Technology Appraisal Guidance [TA487])","year":"2017","author":"National Institute for Health and Care Excellence","key":"e_1_2_5_8_1"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400004521"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119123"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9097-2"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T05:23:25Z","timestamp":1694323405000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/bjh.15912"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15912","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"2019-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}